Main Industry
Biotechnology
Main Product/Service
OncoTeller® integrates multiple proprietary genetic markers developed by MAO YING GENETECH INC., utilizing whole-genome microarrays for RNA quantification to deliver multiple answers from a single test.
(The content above was translated by AI.)
(The content above was translated by AI.)
Founded Year
2012
Unified Business No.
53731167
Status
Active
Number of Employees
0
Total Paid-in
Capital
14,200,000 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
MAO YING GENETECH INC. was established in Taipei City in 2012 and was founded by Dr. Pei-Ying Huang. We possess our own uniquely developed bioinformatics algorithms, through which we analyze and validate big data from biomedical experiments to identify genetic markers that can be applied to disease diagnosis or assist in treatment.
For each research and development project, we first search for suitable data from the vast amount of experimental data stored in biomedical databases, and then use our self-developed algorithms to analyze the data, identify potential marker genes, and design validation methods. Next, we use more relevant biomedical experimental data to validate the genetic markers, and if good results are achieved, we cooperate with hospitals to conduct clinical validation.
(The content above was translated by AI.)
For each research and development project, we first search for suitable data from the vast amount of experimental data stored in biomedical databases, and then use our self-developed algorithms to analyze the data, identify potential marker genes, and design validation methods. Next, we use more relevant biomedical experimental data to validate the genetic markers, and if good results are achieved, we cooperate with hospitals to conduct clinical validation.
(The content above was translated by AI.)
